Effect of the orally administered PKC b Inhibitor, Ruboxistaurin, on sustained moderate visual loss in the PKC-DRS2 Study
Go back to Resources
Effect of the orally administered PKC b Inhibitor, Ruboxistaurin, on sustained moderate visual loss in the PKC-DRS2 Study
Authors:
Location:
Go back to Resources